Clinical trial NCT05966038: ALS/MND Natural History Study Data Repository
Official title: ALS/MND Natural History Study Data Repository
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: ALS
PLS
MND (Motor Neurone DIsease)
Kennedy Disease
PMA - Progressive Muscular Atrophy
PBP - Progressive Bulbar Palsy
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Henry Ford Health System
name: Northwestern University
name: Temple University
name: St. Louis University
name: University of Florida
name: University of Minnesota
name: Virginia Commonwealth University
name: Fondazione Serena Onlus - Centro Clinico NeMO Milano
name: Providence Health & Services
name: University of Pittsburgh
name: Istituti Clinici Scientifici Maugeri SpA
name: Lahey Clinic
name: Hadassah Medical Organization
name: Tel Aviv Medical Center
First posted: 2023-07-28
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All people living with ALS/MND at participating multidisciplinary ALS/MND clinics

Brief summary: This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND).

All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study.

The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform.

The Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license.

Funding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.

Detailed description: Most people with ALS or MND who are seen clinically by the PI or PI designees at participating sites will be recruited into this study. This well-established framework provides an opportunity to offer to a large proportion of people with ALS/MND a chance to participate in a clinical research project.

Upon obtaining consent, the following is done:

People with ALS/MND are assigned a Neurological Global Unique Identifier (NeuroGUID) and its study-specific derivative, NeuroSTAmP, which is used to link this Study's information to biological samples, images, and clinical data obtained from those individuals in this Study and other studies/trials, in which these patients participate(d).

The following information is captured in NeuroBANK platform:

Baseline information

* Longitudinal clinical and phenotypical data from routine clinical visits
* Longitudinal clinical and historical phenotypical data transcribed from electronic health records and notes
* Any other observational data that are of interest to the Investigator may be captured or linked to information in NeuroBANK.

Other Key Features

The site should track numbers of patients who declined participation. The site should have a mechanism in place to include an offer of participation to each patient in clinic (consenting does not require immediate data entry) Regular Data Quality checks may be performed at the site. Site personnel who intend to have access to NeuroBANK are trained and certified prior to given access.

Several registries, both cross-sectional and longitudinal, currently exist in ALS. NeuroBANK is distinct from other current registries in that it is a patient-centered platform that is designed to function as a data repository of patient data from clinical visits and multiple clinical research projects as well as linking these data to biorepository for tissue, imaging, and other biological information. This natural history study can act as a clinical research framework that may link clinical and clinical research data from current and past studies with biological specimens and image collections.

With obtained consents, biological specimens may be collected with bar-coded labels containing patient assigned study specific NeuroSTAmPs, printed from within NeuroBANK, and scanned into NeuroBANK's virtual distributed BioRepository module. Imaging studies are de-identified with NeuroSTAmPs and linked to clinical and phenotypical information. Anonymized clinical data obtained through this protocol are available to other researchers.

Study Population

Individuals who are seen during their clinical care visits are asked to allow their data to be uploaded and captured for clinical research. The NeuroBANK platform is located at and managed by the Center for Innovation and Bioinformatics (CIB), Neurological Clinical Research Institute (NCRI) of Massachusetts General Hospital (Boston, MA).

Consent Process

Every participant in the ALS clinic is approached to participate in this study. A signed informed consent form is obtained before any data are recorded for study purposes.

Eligibility criteria: Inclusion Criteria:

* A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS or
* Other motor neuron disorders, including but not limited to Spinal-Bulbar Muscular Atrophy (SBMA, Kennedy's disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP)

Exclusion Criteria:

* Disease does not meet criteria for any motor neuron disorder

Primary outcomes:
measure: ALS Functional Rating Scale-Revised (ALSFRS-R)
timeFrame: Every 3-4 months up to 5 years
measure: Slow Vital Capacity (SVC)
timeFrame: Every 3-4 months up to 5 years
measure: Survival
timeFrame: Every 3-4 months up to 5 years
Secondary outcomes:
measure: Vital Signs
timeFrame: Every 3-4 months up to 5 years
measure: Neurological Examination
timeFrame: Through study completion, annually up to 5 years
measure: El Escorial Criteria
timeFrame: Through study completion, annually up to 5 years
measure: Handheld Dynamometry
timeFrame: Every 3-4 months up to 5 years
measure: Grip Strength Testing
timeFrame: Every 3-4 months up to 5 years
measure: Rasch Overall ALS Disability Scale (ROADS)
timeFrame: Every 3-4 months up to 5 years
measure: 5 Times Sit to Stand
timeFrame: Every 3-4 months up to 5 years
measure: 10 Meter Walk Test
timeFrame: Every 3-4 months up to 5 years
measure: Physical Examination
timeFrame: Through study completion, annually up to 5 years
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Burlington
country: United States
facility: Lahey Clinic
state: Massachusetts
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
city: Saint Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Portland
country: United States
facility: Providence ALS Clinic
state: Oregon
city: Philadelphia
country: United States
facility: Temple University Lewis Katz School of Medicine
state: Pennsylvania
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
city: Tel Aviv
country: Israel
facility: Tel Aviv Medical Center
city: Milano
country: Italy
facility: Istituti Clinici Scientifici Maugeri SpA
city: Milan
country: Italy
facility: Centro Clinico NEMO Milano
Study officials:
affiliation: Massachusetts General Hospital
name: Alexander Sherman
role: PRINCIPAL_INVESTIGATOR
References: